These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 25007171)
1. Premarket safety and efficacy studies for ADHD medications in children. Bourgeois FT; Kim JM; Mandl KD PLoS One; 2014; 9(7):e102249. PubMed ID: 25007171 [TBL] [Abstract][Full Text] [Related]
2. FDA-approved drugs to treat ADHD. J Psychosoc Nurs Ment Health Serv; 2012 Mar; 50(3):11-2. PubMed ID: 22390784 [No Abstract] [Full Text] [Related]
3. ADHD medication use following FDA risk warnings. Barry CL; Martin A; Busch SH J Ment Health Policy Econ; 2012 Sep; 15(3):119-25. PubMed ID: 23001280 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. Wigal SB CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975 [TBL] [Abstract][Full Text] [Related]
5. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. Nasser A; Hull JT; Chaturvedi SA; Liranso T; Odebo O; Kosheleff AR; Fry N; Cutler AJ; Rubin J; Schwabe S; Childress A CNS Drugs; 2022 Aug; 36(8):897-915. PubMed ID: 35896943 [TBL] [Abstract][Full Text] [Related]
6. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576 [TBL] [Abstract][Full Text] [Related]
7. Can Adverse Event Patterns Inform Shared Decision-Making in ADHD Treatment? A Systematic Review of Evidence From Registration Trials for FDA-Approved Treatments in Adults. Bond JB; Walsh DM; Surman CBH J Psychiatr Pract; 2024 May; 30(3):172-180. PubMed ID: 38819241 [TBL] [Abstract][Full Text] [Related]
8. FDA-Approved Drugs to Treat ADHD. J Psychosoc Nurs Ment Health Serv; 2018 Mar; 56(3):13-14. PubMed ID: 29505085 [No Abstract] [Full Text] [Related]
9. FDA-Approved Drugs to Treat ADHD. J Psychosoc Nurs Ment Health Serv; 2017 Mar; 55(3):17-18. PubMed ID: 28287670 [No Abstract] [Full Text] [Related]
10. FDA-Approved Drugs to Treat ADHD. J Psychosoc Nurs Ment Health Serv; 2020 Mar; 58(3):5-6. PubMed ID: 32129874 [No Abstract] [Full Text] [Related]
11. FDA-Approved Drugs to Treat ADHD. J Psychosoc Nurs Ment Health Serv; 2019 Mar; 57(3):5-6. PubMed ID: 30835794 [No Abstract] [Full Text] [Related]
12. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. Osland ST; Steeves TD; Pringsheim T Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. Najib J Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715 [TBL] [Abstract][Full Text] [Related]
14. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs. Miller JE; Mello MM; Wallach JD; Gudbranson EM; Bohlig B; Ross JS; Gross CP; Bach PB JAMA Netw Open; 2021 May; 4(5):e217075. PubMed ID: 33950209 [TBL] [Abstract][Full Text] [Related]